All In Biotech

Drug Trial Radar · NCT00790673

A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Safety, Tolerability, Biological Activity, and Pharmacokinetics of Orally Administered CF102 in Subjects With Chronic Hepatitis C Genotype 1

Last checked: Nov 19, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Jul 2009

Primary completion

Jun 2011

Study completion Jul 2011

Sponsor

Lead sponsor
Can-Fite BioPharmaIndustry
Sponsor type
Industry
First posted
Nov 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will test the hypothesis that CF102 can safely and effectively suppress viral load in patients with chronic hepatitis C and high circulating levels of virus. The trial will monitor the safety of twice-daily oral dosing with CF102 over a 16-week period; will measure changes in viral load during therapy; and will measure blood concentrations of CF102 at various time points during dosing.

Conditions

  • Chronic Hepatitis C

Interventions

  • CF 102Drug

    Oral capsules

  • PlaceboDrug

    Matching placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event Profile of Repeated Dosing of CF102Time frame: 16 weeks
  2. Effect of Viral LoadTime frame: 16 weeks
  3. Pharmacokinetic Behavior of CF102 During Repeated DosingTime frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rabin Medical Center

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.